Additionally, pharmacological concentrations of EPO activated JAK2/STAT5, RAS/ERK, and PI3K/AKT pathways in NSCLC cells without growth advantage for these cells [47]. This evidence concerns the gene EPO and non-small cell lung carcinoma.